Kush Sehgal

Kush Sehgal

Auto-generated profile, based on publicly available information

Kush Sehgal

Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2024 in Journal of Cataract & Refractive Surgery
Verified
Journal Article
Closed access
SHSara Mbbs Hira
Sara Mbbs Hira
KHKélen Klein Heffel
Kélen Klein Heffel
FMFatima Fcps Mehmood
Fatima Fcps Mehmood
KSKush Mbbs Sehgal
Kush Mbbs Sehgal
ASAna Clara Felix de Farias Santos
Ana Clara Felix de Farias Santos
GVGiulia Steuernagel Del Valle
Giulia Steuernagel Del Valle
Corneal crosslinking (CXL) is used for treating keratoconus and post–laser in situ keratomileusis ectasia. However, refractive surgery is not usually performed with prophylactic CXL. Therefore, we performed a meta-analysis comparing outcomes of refractive surgeries with vs without prophylactic CXL. We systematically searched databases for studies comparing refractive surgeries for myopic correction with vs without prophylactic corneal crosslinking. Review Manager 5.4.1 was used to perform statistical analysis. We included 2820 eyes from 28 studies. Compared with refractive surgery alone, surgery with prophylactic CXL resulted in decreased central corneal thickness, corrected distance visual acuity logMAR, and safety and efficacy indices. There were no significant differences in postoperative uncorrected distance visual acuity of 20/20 or better at ≥12 months and other visual outcomes among both groups. More randomized controlled trials with standard crosslinking protocols are needed to analyze the prophylactic use of crosslinking with refractive surgeries.

22 February 2025 in Asian Journal of Psychiatry
Verified
Journal Article
Closed access
MAMateus Rodrigues Alessi
Mateus Rodrigues Alessi
DBDouglas Barroso
Douglas Barroso
EBEduardo Cerchi Barbosa
Eduardo Cerchi Barbosa
KSKush Sehgal
Kush Sehgal
GVGustavo Hayasaki Vieira
Gustavo Hayasaki Vieira
ALAndrea Gonzalez Lezana
Andrea Gonzalez Lezana

19 January 2026 in CNS Drugs
Verified
Journal Article
Closed access
PDF file
MIMinahil Iqbal
Minahil Iqbal
PMParth Modi
Parth Modi
KSKush Sehgal
Kush Sehgal
GCGabriel P. A. Costa
Gabriel P. A. Costa
GBGargi Bhattacharya
Gargi Bhattacharya
AAAkhil Anand
Akhil Anand

18 September 2024 in Revista Brasileira de Ginecologia e Obstetrícia
Verified
Journal Article
Open access
PDF file
ASAna Clara Felix de Farias Santos
Ana Clara Felix de Farias Santos
FZFernanda Valeriano Zamora
Fernanda Valeriano Zamora
Lubna Al-SharifLubna Al-Sharif
Lubna Al-Sharif
KSKush Sehgal
Kush Sehgal
Deivyd Vieira Silva CavalcanteDeivyd Vieira Silva Cavalcante
Deivyd Vieira Silva Cavalcante
PSPedro Henrique Costa Matos da Silva
Pedro Henrique Costa Matos da Silva
Objective To compare outcomes in patients with repeated implantation failure undergoing Intracytoplasmic Sperm Injection/In vitro fertilization (IVF/ICSI) plus immunosuppressants such as prednisolone, prednisone, or cyclosporine A versus the use of IVF/ICSI alone. Data source Databases were systematically searched in PubMed, Cochrane, and Embase databases in September 2023. Study Selection Randomized clinical trials and observational […] Abstract Objective To compare outcomes in patients with repeated implantation failure undergoing Intracytoplasmic Sperm Injection/In vitro fertilization (IVF/ICSI) plus immunosuppressants such as prednisolone, prednisone, or cyclosporine A versus the use of IVF/ICSI alone. Data source Databases were systematically searched in PubMed, Cochrane, and Embase databases in September 2023. Study Selection Randomized clinical trials and observational […]

13 July 2026 in Substance use & addiction journal
Verified
Journal Article
Closed access
KSKush Sehgal
Kush Sehgal
ALAna Carolina Leal
Ana Carolina Leal
LBLeticia Mara dos Santos Barbetta
Leticia Mara dos Santos Barbetta
NNNeil Nero
Neil Nero
AAAkhil Anand
Akhil Anand
Background: Shared medical appointments (SMAs) integrate group-based clinical care with individual medical management and are increasingly used in the treatment of substance use disorders (SUDs) to improve access, engagement, and care coordination. However, their use, outcomes, and implementation in SUD care have not been systematically synthesized. Methods: We conducted a systematic review registered with PROSPERO (CRD42025639504). MEDLINE, Embase, PsycINFO, Scopus, and Cochrane Central were searched from database inception through September 2025. Randomized controlled trials, observational studies, and qualitative studies examining SMAs among adults with SUDs were included. Outcomes of interest included treatment engagement and retention, substance use outcomes, mental health and patient-reported outcomes, and implementation characteristics. Study quality was assessed across quantitative and qualitative designs, and findings were synthesized descriptively. Results: Fourteen studies, representing approximately 578 participants, met inclusion criteria. Twelve studies focused exclusively on opioid use disorder, 1 included both alcohol and opioid use disorders, and 1 did not specify substance type. Treatment retention was reported in 6 studies, with a median 6-month retention of 72.9%. Three studies reported reductions in substance use outcomes, and 2 reported improvements in depression or anxiety. Qualitative studies consistently described high patient satisfaction, peer support, and shared accountability. Implementation studies demonstrated feasibility across diverse outpatient settings, with substantial heterogeneity across study designs and outcomes. Conclusions: SMAs appear feasible and acceptable for addiction care and may support treatment retention and patient experience. Evidence remains heterogeneous and largely observational, highlighting the need for rigorous comparative studies to better define effectiveness and implementation.

18 September 2026 in Journal of Clinical Psychopharmacology
Verified
Journal Article
Closed access
VOVivien Obitulata
Vivien Obitulata
KSKush Sehgal
Kush Sehgal
JFJuan Diego Freire Florez
Juan Diego Freire Florez
MMMichelle Mussi
Michelle Mussi
NNNeil Nero
Neil Nero
AAAkhil Anand
Akhil Anand
Purpose: Zonisamide, an anticonvulsant with GABAergic and glutamatergic effects, has been investigated as a treatment for alcohol use disorder (AUD), but its efficacy and tolerability remain uncertain. This systematic review and meta-analysis synthesizes evidence from randomized controlled trials evaluating zonisamide for AUD. Procedures: We searched MEDLINE, Embase, PsycINFO, Scopus, and CENTRAL from inception through June 23, 2025, with an updated search on March 31, 2026, for randomized controlled trials comparing zonisamide to placebo in adults with AUD. The primary outcome was a reduction in alcohol use. Data were pooled using random-effects meta-analyses. Risk of bias was assessed using the Cochrane Risk of Bias 2 tool. Findings: Five randomized controlled trials (N=344) met inclusion criteria. Zonisamide significantly reduced drinks per day (MD=−0.79; 95% CI=−0.95 to −0.63; P <0.001) and drinking days (MD=−7.93; 95% CI=−11.03 to −4.83; P <0.001). No significant effect was observed for heavy drinking days (MD=−0.95; 95% CI=−2.12 to 0.22; P =0.11), with high heterogeneity ( I ²=91%). Zonisamide was associated with a significantly lower rate of nervousness, anxiety, or irritability (RR=0.53; 95% CI=0.34-0.84; P =0.007); other adverse events did not differ from placebo. Implications: Zonisamide reduced drinks per day and drinking days but not heavy drinking days, suggesting a selective benefit on overall consumption. A protective effect on nervousness, anxiety, and irritability was also observed, consistent with zonisamide’s GABAergic mechanism. Further well-powered trials are needed to inform clinical recommendations.